Clinical Trial Update: A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of Zanubrutinib and Tislelizumab in patients with Large B-cell Lymphoma who progressed after CAR-T therapy; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Large B-cell Lymphoma

Drugs mentioned

• Tislelizumab (tislelizumab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Large B-cell Lymphoma | Phase 2 | Status: RECRUITING